GE Blood Glucose Monitoring System 180, GE Blood Glucose Monitoring System 182, Rightest Blood Glucose Monitoring System GM280, Rightest Blood Glucose Monitoring System GM280B,

K170143 · Bionime Corporation · NBW · Jul 6, 2017 · Clinical Chemistry

Device Facts

• Record ID: K170143
• Device Name: GE Blood Glucose Monitoring System 180, GE Blood Glucose Monitoring System 182, Rightest Blood Glucose Monitoring System GM280, Rightest Blood Glucose Monitoring System GM280B,
• Applicant: Bionime Corporation
• Product Code: NBW · Clinical Chemistry
• Decision Date: Jul 6, 2017
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.1345
• Device Class: Class 2
• Attributes: Pediatric

Indications for Use

The Rightest Blood Glucose Monitoring System GM280 is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm. The Rightest Blood Glucose Monitoring System GM280 is intended to be used by a single person and should not be shared. The Rightest Blood Glucose Monitoring System GM280 is intended for self- testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Rightest Blood Glucose Monitoring System should not be used for the diagnosis of, or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly). The Rightest Blood Glucose Test Strip GS280 is used with Rightest meter GM280 for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

Device Story

System measures capillary whole blood glucose via amperometric assay (glucose oxidase/potassium ferricyanide). User applies 0.75 µL blood sample to test strip; meter detects current proportional to glucose concentration; displays result in mg/dL. Designed for single-patient home use; GM280B and GE182 models include Bluetooth 4.0 for data transmission. Meter performs auto-coding upon strip insertion. Provides aid for monitoring diabetes control; not for diagnostic or screening purposes. Contraindicated for neonates, critically ill, or rapid glucose changes (AST). Benefits include convenient home monitoring and data tracking.

Clinical Evidence

User performance study (n=135) evaluated accuracy of self-testing on fingertip, palm, and forearm compared to YSI 2300 laboratory reference. Results showed high correlation (R²=0.99) across sites. Fingertip testing met accuracy criteria (100% within ±20% for glucose ≥75 mg/dL). Bench testing confirmed precision, linearity, interference resistance, and environmental robustness.

Technological Characteristics

Glucose oxidase electrochemical sensor; 0.75 µL sample volume; 5-second measurement time; 20-600 mg/dL range; 20-60% hematocrit range. GM280/180 use CR2032 battery; GM280B/182 use two AAA batteries. Connectivity: GM280B features Bluetooth 4.0 (Low Energy). Auto-coding. LCD display.

Indications for Use

Indicated for quantitative measurement of glucose in fresh capillary whole blood (fingertip, forearm, palm) by people with diabetes at home to monitor diabetes control. Not for diagnosis, screening, or neonatal use. Alternative site testing only during steady-state glucose levels.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Predicate Devices

• GE333 Blood Glucose Monitoring System (K143387)

Submission Summary (Full Text)

{0}

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number:
K170143

B. Purpose for Submission:
New Device

C. Measurand:
Capillary whole blood glucose from the fingertip, forearm, or palm.

D. Type of Test:
Quantitative amperometric assay (Glucose Oxidase)

E. Applicant:
Bionime Corporation

F. Proprietary and Established Names:
Rightest Blood Glucose Monitoring System GM280
Rightest Blood Glucose Monitoring System GM280B
GE Blood Glucose Monitoring System 180
GE Blood Glucose Monitoring System 182

G. Regulatory Information:
1. Regulation section:
21 CFR 862.1345, Glucose test system
2. Classification:
Class II

{1}

3. Product code:
NBW, System Test, Blood Glucose, Over the Counter

4. Panel:
Clinical Chemistry (75)

H. Intended Use:

1. Intended use(s):
See indication(s) for use below

2. Indication(s) for use:

**Rightest Blood glucose monitoring System GM280**

The Rightest Blood Glucose Monitoring System GM280 is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm. The Rightest Blood Glucose Monitoring System GM280 is intended to be used by a single person and should not be shared.

The Rightest Blood Glucose Monitoring System GM280 intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Rightest Blood Glucose Monitoring System should not be used for the diagnosis of, or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady-state times (when glucose is not changing rapidly).

The Rightest Blood Glucose Test Strip GS280 is used with Rightest meter GM280 for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

**Rightest Blood glucose monitoring System GM280B**

The Rightest Blood Glucose Monitoring System GM280B is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm. The Rightest Blood Glucose Monitoring System GM280B is intended to be used by a single person and should not be shared.

The Rightest Blood Glucose Monitoring System GM280B intended for self-testing

{2}

outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Rightest Blood Glucose Monitoring System should not be used for the diagnosis of, or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The Rightest Blood Glucose Test Strip GS280 is used with Rightest meter GM280B for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

## GE Blood glucose monitoring System 180

The GE Blood Glucose Monitoring System 180 is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm. The GE Blood Glucose Monitoring System 180 is intended to be used by a single person and should not be shared.

The GE Blood Glucose Monitoring System 180 intended for self- testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GE Blood Glucose Monitoring System 180 should not be used for the diagnosis of, or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The GE Blood Glucose Strip 180 is used with GE Blood Glucose Monitoring Meter 180 for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

## GE Blood glucose monitoring System 182

The GE Blood Glucose Monitoring System 182 is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm. The GE Blood Glucose Monitoring System 182 is intended to be used by a single person and should not be shared.

The GE Blood Glucose Monitoring System 182 intended for self- testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The GE Blood Glucose Monitoring System 182 should not be used for the diagnosis of, or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing

{3}

rapidly).

The GE Blood Glucose Strip 180 is used with GE Blood Glucose Monitoring Meter 182 for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

3. Special conditions for use statement(s):

- These systems can only use with capillary whole blood samples.
- Not for screening or diagnosis of diabetes mellitus.
- Not for use in the critically ill.
- These systems should not be used for neonates.
- These devices are not intended for use in healthcare or assisted-use settings such as hospitals, physician offices, or long-term care facilities because it has not been Contains Nonbinding Recommendations cleared by FDA for use in these settings, including for routine assisted testing or as part of glycemic control procedures. Use of this device on multiple patients may lead to transmission of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), or other bloodborne pathogens.
- The blood glucose result of the meter may be much lower than "true glucose levels" in the hyperglycemic-hyperosmolar state, with or without ketosis.
- Severe dehydration and excessive water loss may cause inaccurately low results.
- Patients going through oxygen therapy may yield falsely low results
- Storage of strips near bleach as well as bleach containing products will affect the results of the Rightest® Test Strips.
- Do not use at altitudes greater than 10,000 feet (3,048 meters).
- Hematocrit range is 20–60%. Check with your healthcare provider if you do not know your hematocrit level.
- If you are taking high dose of vitamin C (blood concentration > 3 mg/dL), the result from your meter may not be correct.
- If you have a condition that may cause your blood levels of uric acid to increase (uric acid >12 mg/dL), such as kidney disease or gout, then the results from your meter may not be correct.
- DO NOT test on the palm or forearm to calibrate continuous glucose monitors (CGMs).
- DO NOT test on the palm or forearm if you are testing for insulin dose calculations or hypoglycemia (Low blood glucose).
- Do not test the blood sample from palm or forearm when glucose is changing rapidly (senarios: after drinking, after meal, after exercise).

{4}

4. Special instrument requirements:

Rightest Blood Glucose Meter GM280
Rightest Blood Glucose Meter GM280B
GE Blood Glucose Meter 180
GE Blood Glucose Meter 182

I. Device Description:

Rightest GM280 Blood Glucose Monitoring System, Rightest 280B Blood Glucose Monitoring System, GE 180 Blood Glucose Monitoring System, and GE 182 Blood Glucose Monitoring System consists of the following devices: Blood Glucose Meter, Blood Glucose Test Strip, three levels of Control Solutions (Level 1, Level 2 and Level 4), lancing device and sterile lancets. GM280B and GE182 Blood Glucose Monitoring Systems also containing Bluetooth connectivity capabilities.

J. Substantial Equivalence Information:

1. Predicate device name(s):

Bionime Corporation GE333 Blood Glucose Monitoring System

2. Predicate 510(k) number(s):

K143387

3. Comparison with predicate:

The different models of the proposed devices are identical except in name, two model (Rightest 280B and GE182) have Bluetooth capabilities.

{5}

| Similarities | | | |
| --- | --- | --- | --- |
| Item | Device | | Predicate |
| | Rightest Blood Glucose Monitoring System GM280 | Rightest Blood Glucose Monitoring System GM280B | GE333 Blood Glucose Monitoring System k143387 |
| | GE Blood Glucose Monitoring System 180 | GE Blood Glucose Monitoring System 182 | |
| Indications for Use | Intended for the quantitative measurement of glucose in fresh capillary blood samples by people with diabetes at home to monitor the effectiveness of diabetes control | | Same |
| Measurement Technology | Glucose Oxidase Electrochemical Sensor | | Same |
| Sample Type | Capillary whole blood | | Same |
| Minimum Sample Volume | 0.75 μL | | Same |
| Primary Site Testing | Fingertip | | Same |
| Alternative Site Testing | Forearm, Palm | | Same |
| Unit of Measurement | mg/dL | | Same |
| Measuring Range | 20-600 mg/dL | | Same |
| Measuring Time | 5 seconds | | Same |
| Hematocrit | 20-60 % | | Same |
| Control Solution | 3 levels (Level 1, 2, and 4) Rightest Control Solution GC550 | | Same |
| Maximum Altitude | 3275 m (10745 feet) | | Same |
| Operating Conditions | Temperature 10 ~ 40°C (50 ~104 °F), 10 ~ 90% Relative Humidity | | Same |
| Meter Storage Conditions | -10 ~ 60°C (14 ~140 °F) | | Same |
| Test Strip Storage Conditions | 4 ~ 30°C (39 ~86 °F), 10-90 | | Same |

{6}

| Similarities | | | |
| --- | --- | --- | --- |
| Item | Device | | Predicate |
| | Rightest Blood Glucose Monitoring System GM280 | Rightest Blood Glucose Monitoring System GM280B | GE333 Blood Glucose Monitoring System k143387 |
| | GE Blood Glucose Monitoring System 180 | GE Blood Glucose Monitoring System 182 | |
| | % relative humidity | | |
| Test Strip Shelf Life (After Opening) | 3 months | | Same |
| Memory Capacity | 500 blood glucose test results with date and time | | Same |
| Power Saving | Turn off automatically 2 minutes after last user action / Press the main button for 3 seconds. | | Same |
| Coding | Auto coding | | Same |
| Monitor | LCD display | | Same |
| Backlight | No | | Same |
| Differences | | | |
| --- | --- | --- | --- |
| Item | Device | | Predicate |
| | Rightest GM280 | Rightest GM280B | GE333 Blood Glucose Monitoring System k143387 |
| | GE180 | GE182 | |
| Wireless module | None | Bluetooth 4.0 (Low energy) | Bluetooth 4.0 (Low energy) |
| Power Supply | One CR2032 battery | | Two AAA batteries |
| Battery Life | 1000 tests | | About 800 tests |
| LCD display area | 34 mm*27.5mm | | 39mm*39.5mm |
| Meter Weight | 43.0±5g with batteries | | 81.0 ± 5g with batteries |
| Color | white/gray | | white/green |

{7}

K. Standard/Guidance Document Referenced (if applicable):

CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition (2005)

CLSI EP6-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (2014)

EN 61010-1, Safety requirements for electrical equipment for measurement, control, and laboratory use - Part 1: General requirements (2001)

L. Test Principle:

The Rightest GM280 Blood Glucose Monitoring System, Rightest 280B Blood Glucose Monitoring System, GE 180 Blood Glucose Monitoring System, and GE 182 Blood Glucose Monitoring System measures glucose amperometrically. The reaction of glucose oxidase and potassium ferricyanide in the test strip with glucose in the sample produces an electrical current which is proportional to the amount of glucose in the sample. The meter measures the current and converts it to the corresponding glucose concentration, which is displayed on the meter.

M. Performance Characteristics (if/when applicable):

There are no differences between the Rightest GM280 Blood Glucose Monitoring System, Rightest 280B Blood Glucose Monitoring System, GE 180 Blood Glucose Monitoring System, and GE 182 Blood Glucose Monitoring System except for Bluetooth capabilities in the GM280B and GE182 meters. Therefore, analytical studies were conducted on the GM280B device to support the four systems.

1. Analytical performance:

a. Precision/Reproducibility:

Within-run (Repeatability)

Within-run precision studies were performed using venous whole blood samples of 5 glucose levels (30-50, 51-110, 111-150, 151-250, 251-400 mg/dL). Samples were tested ten times with each of three lots of single test strips with 10 meters for a total of 300 tests per glucose concentration. Results are summarized below:

{8}

| Glucose Level (mg/dL) | Lot | Mean (mg/dL) | SD (mg/dL) | CV (%) |
| --- | --- | --- | --- | --- |
| 30-50 | 1 | 42.1 | 1.5 | 3.5% |
| | 2 | 41.2 | 1.2 | 2.9% |
| | 3 | 40.4 | 1.3 | 3.2% |
| 51-110 | 1 | 98.8 | 1.9 | 1.9% |
| | 2 | 96.4 | 2.4 | 2.5% |
| | 3 | 95.7 | 2.4 | 2.5% |
| 111-150 | 1 | 134.3 | 3.1 | 2.3% |
| | 2 | 129.3 | 3.2 | 2.4% |
| | 3 | 129.5 | 2.7 | 2.1% |
| 151-250 | 1 | 233.7 | 5.0 | 2.1% |
| | 2 | 227.6 | 5.1 | 2.3% |
| | 3 | 227.7 | 4.5 | 2.0% |
| 251-400 | 1 | 383.1 | 6.7 | 1.8% |
| | 2 | 375.6 | 6.9 | 1.8% |
| | 3 | 373.8 | 5.6 | 1.5% |

## Intermediate Precision

Intermediate (between run) precision was evaluated using three levels of glucose control solutions, 3 test strip lots, and 10 meters. Each control solution level was measured once a day for 10 days with each meter and test strip lot, for a total of 100 replicates per control solution level per test strip lot for a total of 300 replicate for each glucose control level. Results are summarized below:

| Control Solution Level (mg/dL) | Lot | Mean (mg/dL) | SD (mg/dL) | CV (%) |
| --- | --- | --- | --- | --- |
| 30-50 | 1 | 38.9 | 1.0 | 2.7% |
| | 2 | 38.2 | 1.2 | 3.1% |
| | 3 | 37.4 | 1.2 | 3.2% |
| 51-110 | 1 | 96.4 | 1.6 | 1.6% |
| | 2 | 96.6 | 1.5 | 1.5% |
| | 3 | 95.9 | 1.6 | 1.6% |
| 251-400 | 1 | 280.6 | 4.4 | 1.6% |
| | 2 | 276.3 | 3.6 | 1.3% |
| | 3 | 278.6 | 4.2 | 1.5% |

{9}

b. Linearity/assay reportable range:

Linearity was assessed with three lots of GS280 Blood Glucose Test Strips. Each test strip lot was tested with three GM280 Blood Glucose Monitoring Systems using blood samples spiked to 15 glucose levels (0, 13.7, 24.0, 57.6, 117, 165, 225, 265, 325, 375, 429, 475, 535, 552, and 635 mg/dL). Each sample was measured in triplicate with each Rightest Blood Glucose Monitoring System GM280 and measured in duplicate with a laboratory method (YSI 2300 glucose analyzer). The observed meter values were averaged and compared with the mean of duplicate reference method measurements

The evaluation yielded the following regression equations for each of three lots based on all samples:

Lot 1: y = 0.9929x + 1.5820; R² = 0.9992

Lot 2: y = 0.9926x + 1.1366; R² = 0.9983

Lot 3: y = 0.9917x + 2.3442; R² = 0.9992

These studies support the claimed analytical measuring range of the systems. If a sample reading falls outside of the measuring range of the device, a "LO" or "HIGH" message appears instead of a value. These features were tested and shown to function as intended.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability

The systems are traceable to the NIST SRM 917c glucose reference material.

Test Strip Stability

Test Strip stability has been evaluated through accelerated and real-time open vial and closed vial studies. Protocols and acceptance criteria were reviewed and found to be acceptable to support the claimed shelf life stability and open vial stability of 24 months from manufacture when stored at 40- 86°F (4-30°C) and 10-90% relative humidity.

d. Detection limit:

See the linearity studies (section M.1.b.) above.

{10}

# e. Analytical specificity:

The interference study for Rightest GM280 BGMS was performed using 2 glucose concentration levels (50-100 and $250 - 350\mathrm{mg / dL}$ ) of venous blood samples and 26 interference substances. 10 meters and 3 lots of test strips were used to perform 10 replicates per lot and compared to an established laboratory reference method (YSI 2300 Analyzer). The sponsor defined significant interference as of bias greater than $\pm 10\%$ (vs reference method). The compounds at the concentrations listed below did not demonstrate significant interference:

| Potential Interferent | Highest concentration tested at which no significant interference is observed (mg/dL) |
| --- | --- |
| Acetaminophen | 20 |
| Ascorbic Acid | 3 |
| Dopamine HCl | 1.25 |
| EDTA | 0.1 |
| Gentisic Acid | 1.8 |
| Heparin | 18.75 U/ml |
| Ibuprofen | 50 |
| L-Dopa | 3 |
| MethylDopa | 1.5 |
| Pralidoxime iodide | 4 |
| Salicylic Acid | 60 |
| Tetracycline | 1.5 |
| Tolazamide | 40 |
| Tolbutamide | 64 |
| Bilirubin-unconjugated | 50 |
| Cholesterol | 700 |
| Creatinine HCl | 10 |
| Glutathione reduced | 40 |
| Hemoglobin | 6000 |
| Triglycerides | 3000 |
| Uric Acid | 12 |
| Maltose | 280 |
| Xylose | 200 |
| Galactose | 200 |
| Lactose | 50 |
| Icodextrin | 1000 |

{11}

Based on these results, the sponsor includes the following in their test strip labeling:

- If you are taking high dose of vitamin C (blood concentration > 3 mg/dL), the result from your meter may not be correct.
- If you have a condition that may cause your blood levels of uric acid to increase (uric acid ≥12 mg/dL), such as kidney disease or gout, then the results from your meter may not be correct.

f. Assay cut-off:

Not Applicable

2. Comparison studies:

a. Method comparison with predicate device:

Not Applicable

b. Matrix comparison:

Not Applicable

3. Clinical studies:

a. Clinical Sensitivity:

Not Applicable

b. Clinical specificity:

Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable):

User Performance Studies

To assess the accuracy of the Rightest Blood Glucose Monitoring System GM280/GM280B in the hands of the intended users, 135 lay users tested their own fingertip capillary blood samples. 135 users also took capillary blood samples from their palms and 133 users took capillary samples from their forearms. Results were compared to the measurements made using a laboratory comparator method (YSI 2300 analyzer). Samples ranged in glucose concentration from 66 – 350 mg/dL. The

{12}

meter results relative to YSI are summarized below:

| Testing Site | Linear Equation | R2 |
| --- | --- | --- |
| Fingertip | y = 0.99x + 1.33 | 0.99 |
| Palm | y = 0.99x + 1.81 | 0.99 |
| Forearm | y = 0.96x + 4.40 | 0.99 |

# Fingertip Capillary Samples

For glucose concentrations $< 75\mathrm{mg / dL}$

| Within ±5mg/dL | Within ±10mg/dL | Within ±15mg/dL |
| --- | --- | --- |
| 2/4 (50%) | 4/4 (100%) | 4/4 (100.0%) |

For glucose concentrations $\geq 75\mathrm{mg / dL}$

| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 87/131 (66.4%) | 119/131 (90.8%) | 129/131 (98.5%) | 131/131 (100%) |

# Palm Capillary Samples (AST Samples)

For glucose concentrations $< 75\mathrm{mg / dL}$

| Within ±5mg/dL | Within ±10mg/dL | Within ±15mg/dL |
| --- | --- | --- |
| 2/4 (50%) | 4/4 (100%) | 4/4 (100.0%) |

For glucose concentrations $\geq 75\mathrm{mg / dL}$

| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 75/131 (57.3%) | 114/131 (87.0%) | 128/131 (97.7%) | 129/131 (98.5%) |

# Forearm Capillary Samples (AST Samples)

For glucose concentrations $< 75\mathrm{mg / dL}$

| Within ±5mg/dL | Within ±10mg/dL | Within ±15mg/dL |
| --- | --- | --- |
| 1/3 (33%) | 2/3 (66.7%) | 3/3 (100%) |

For glucose concentrations $\geq 75\mathrm{mg / dL}$

| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 67/130 (51.5%0 | 105/130 (80.8%) | 125/130 (96.2%) | 129/130 (99.2%) |

A readability assessment indicated a Flesch-Kincaid Score of 8 and lower for all instructional materials included with this device.

# 4. Clinical cut-off:

{13}

Not Applicable

5. Expected values/Reference range:

Expected glucose values for persons without diabetes:

| Status | Range (mg/dL) |
| --- | --- |
| Fasting | <100 mg/dL |
| Two hours after meals | 140 mg/dL |

American diabetes association. Standards of medical care in diabetes-2016. 2016;39 (supp. 1 diabetes Care): S8-S16

N. Instrument Name:

Rightest Blood Glucose Monitoring Meter GM280
Rightest Blood Glucose Monitoring Meter GM280B
GE Blood Glucose Monitoring Meter 180
GE Blood Glucose Monitoring Meter 182

O. System Descriptions:

1. Modes of Operation:

Each test strip is single use and requires a sample volume of 0.75 µL.

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?

☐ Yes ☐ X ☐ or No

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?

☐ Yes ☐ X ☐ or No

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

☐ Yes ☐ X ☐ or No

{14}

3. Specimen Identification:
There is no sample identification function with these devices. Samples are applied directly to the test strips as they are collected.

4. Specimen Sampling and Handling:
The glucose test is intended to be used with capillary whole blood from the fingertip, palm or forearm. The whole blood sample is applied directly to the test strip by capillary action.

5. Calibration:
There is no calibration required by the user for the Rightest GM280 Blood Glucose Monitoring System, Rightest 280B Blood Glucose Monitoring System, GE 180 Blood Glucose Monitoring System, GE 182 Blood Glucose Monitoring System. The meter is automatically coded when the test strip is inserted into the meter.

6. Quality Control:
Recommendations on when to test the control materials are provided in the labeling. An acceptable range for each control level is printed on the test strip vial labels. The user is cautioned not to use the meter if the control result falls outside these ranges. Control results are stored along with the blood results. The control solution tests are differentiated by a control solution symbol.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:

1. Sample Volume Study
To evaluate the minimal sample volume of the blood glucose test strips, accuracy of the system with blood volumes of 0.60 μL, 0.65 μL, 0.70 μL, 0.75 μL, 0.80 μL, 1.00 μL, 1.25 μL, 2.00 μL, and 3.00 μL was assessed. Three blood glucose meters were used in this assessment and three lots of test strips to evaluate three blood glucose concentrations (50-75, 80 - 120 mg/dL, and 270 - 330 mg/dL). This testing supported the claimed minimum sample volume of 0.75 for this device and that the sample detection feature functioned appropriately when the sample volume was &lt;0.75 uL.

2. Altitude Study
To evaluate the effects of altitude on system performance, three test strip lots were tested with 3 meters using three whole blood samples with glucose concentrations of 47.5-52.5, 92-100, and 283-307 mg/dL. The samples were tested at 0, 3280, 6561, and 10745 feet above sea level. Results obtained were compared with those obtained with an established

{15}

laboratory reference method (YSI 2300 analyzer). The results demonstrate acceptable bias relative to the reference method to support the claim in the labeling that altitudes up to 10,745 ft. (3275 meters) do not affect device performance.

## 3. Hematocrit Study

The effect of different hematocrit levels was evaluated using whole blood. Rightest Blood Glucose Monitoring System GM280/GM280B was tested with venous blood at six glucose concentration intervals (20-50, 60-80, 135-165, 180-220, 270-330 and 360-440 mg/dL) and nine hematocrit levels (10, 20, 25, 30, 40, 55, 60, 65 and 70%). Each sample was measured in five replicates for each of three test strip lots also with an established laboratory comparator method (YSI). Results of samples at each hematocrit level were compared to samples measured with an established laboratory reference method (YSI) and support the claimed hematocrit range of 20-60%.

## 4. Test System Operating Conditions

Three Rightest Blood Glucose Monitoring System GM280/GM280B Meters were used to test venous blood sample with three lots of blood glucose test strips. Six test conditions were used in this study: 50 °F/ 10% RH, 50 °C/ 90% RH, 77 °C/ 10% RH, 77 °C/ 90% RH, 104 °C/ 10% RH, 104 °C/ 90% RH. The results of this study supported the sponsor's claimed operating conditions of 50 °F-104 °F and a relative humidity range of 10% to 90%.

## 5. EMC Testing

The sponsor provided documentation certifying that acceptable electromagnetic testing (EMC) had been performed and the device system was found compliant.

## 6. Infection Control Studies

The device is intended for a single-patient use only. Disinfection efficacy studies were performed on the materials comprising the polycarbonate, acrylonitrile butadiene styrene plus polycarbonate meters by an outside commercial testing laboratory demonstrating complete inactivation of hepatitis B virus (HBV) with the chosen disinfectant, Cavi Wipes disinfecting towelettes (EPA Registration Number 46781-8). Robustness studies were also performed by the sponsor demonstrating that there was no change in performance or external materials of the meter. The robustness studies were designed to simulate cleaning and disinfection procedures 8 times a month for a total of 550 times in a meter's five-year lifetime. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.

{16}

7. This device was cleared after the FDA issued final guidance documents for prescription use blood glucose monitoring systems (BGMS) and over-the-counter use blood glucose monitoring systems (SMBG). However, the recommendations in the guidance documents were not followed for this device since the submission was received prior to the finalization of the guidance documents.

Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.